Investigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European view [PDF]
, 2022 Excessive daytime sleepiness (EDS) is a major symptom of obstructive sleep apnoea (OSA), defined as the inability to stay awake during the day. Its clinical descriptors remain elusive, and the pathogenesis is complex, with disorders such as insufficient
Asin, Jerryll +7 more
core +1 more source
Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment A Randomized Trial [PDF]
, 2020 Rationale: Excessive daytime sleepiness is a common disabling symptom in obstructive sleep apnea syndrome. Objectives: To evaluate the efficacy and safety of pitolisant, a selective histamine H3 receptor antagonist with wake-promoting effects, for the ...
Dauvilliers, Yves +4 more
core +4 more sources
European guideline and expert statements on the management of narcolepsy in adults and children [PDF]
, 2021 Background and purpose: Narcolepsy is an uncommon hypothalamic disorder of presumed autoimmune origin that usually requires lifelong treatment. This paper aims to provide evidence-based guidelines for the management of narcolepsy in both adults and ...
Baldin, Elisa +17 more
core +11 more sources
Obstructive Sleep Apnoea Treatments-Where Are We Now? [PDF]
RespirologyRespirology, Volume 30, Issue 10, Page 920-922, October 2025.
Luu S, Lee D, Yee BJ.
europepmc +2 more sources
Pitolisant for Residual Excessive Daytime Sleepiness in OSA Patients Adhering to CPAP A Randomized Trial [PDF]
, 2021 BACKGROUND: Excessive daytime sleepiness (EDS) in individuals with OSA syndrome persisting despite good adherence to CPAP is a disabling condition. Pitolisant is a selective histamine H3-receptor antagonist with wake-promoting effects. RESEARCH QUESTION:
Dauvilliers, Yves +5 more
core +1 more source
Correction to: SURWEY real-world study of solriamfetol: initiation, titration, safety, efficacy, and follow-up experience for patients with obstructive sleep apnea in Germany. [PDF]
Sleep BreathWinter Y +6 more
europepmc +2 more sources
Sleep, 2021 Abstract Introduction Solriamfetol (Sunosi®), a dopamine/norepinephrine reuptake inhibitor, is approved (US and EU) to treat excessive daytime sleepiness (EDS) in adults with narcolepsy (75–150 mg/day) or obstructive sleep apnea (OSA) (37.5–150 mg/day).
Michael Thorpy +6 more
openaire +1 more source
New Trends in the Quality Control of Enantiomeric Drugs: Quality by Design-Compliant Development of Chiral Capillary Electrophoresis Methods [PDF]
, 2022 Capillary electrophoresis (CE) is a potent method for analyzing chiral substances and is commonly used in the enantioseparation and chiral purity control of pharmaceuticals from different matrices.
Furlanetto S. +6 more
core +1 more source
Autonomic Dysfunction in Hypersomnia [PDF]
, 2023 Purpose of Review: This article provides a comprehensive overview of the literature on autonomic dysfunctions in centraldisorders of hypersomnolence: narcolepsy type 1 and type 2, idiopathic hypersomnia, and the Kleine-Levin syndrome.
Alessandro Silvani +4 more
core +1 more source
Post-marketing safety profile of solriamfetol: A real-world disproportionality analysis using FDA adverse event reporting system (FAERS) database. [PDF]
HeliyonSolriamfetol is a selective dopamine and noradrenalin reuptake inhibitor applied in adult patients with excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA).
He B, Zheng W.
europepmc +2 more sources